CART84

CART84 is a CAR-T cell therapy developed by Gyala Therapeutics. Its target is CD3 (the sponsor names CD84). The sponsor states: Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells. ClinicalTrials.gov describes the intervention as: GYA01 (CART84): autologous cell-based product containing CD3+ T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor (CAR). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute myeloid leukaemia. The largest, NCT07471789, plans to enrol 33 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.